vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and PAVmed Inc. (PAVM). Click either name above to swap in a different company.

INVO Fertility, Inc. is the larger business by last-quarter revenue ($1.8M vs $996.0K, roughly 1.8× PAVmed Inc.). PAVmed Inc. runs the higher net margin — 6465.8% vs -150.5%, a 6616.3% gap on every dollar of revenue. On growth, PAVmed Inc. posted the faster year-over-year revenue change (25.9% vs 22.6%). INVO Fertility, Inc. produced more free cash flow last quarter ($-1.8M vs $-8.9M).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

PAVmed Inc. is a commercial-stage medical technology company that designs, develops and commercializes innovative diagnostic and therapeutic medical products. Its portfolio covers point-of-care diagnostics, interventional oncology and gastroenterology solutions, primarily serving healthcare providers and patients across the United States.

IVF vs PAVM — Head-to-Head

Bigger by revenue
IVF
IVF
1.8× larger
IVF
$1.8M
$996.0K
PAVM
Growing faster (revenue YoY)
PAVM
PAVM
+3.3% gap
PAVM
25.9%
22.6%
IVF
Higher net margin
PAVM
PAVM
6616.3% more per $
PAVM
6465.8%
-150.5%
IVF
More free cash flow
IVF
IVF
$7.1M more FCF
IVF
$-1.8M
$-8.9M
PAVM

Income Statement — Q3 FY2025 vs Q3 FY2024

Metric
IVF
IVF
PAVM
PAVM
Revenue
$1.8M
$996.0K
Net Profit
$-2.6M
$64.4M
Gross Margin
-38.7%
Operating Margin
-93.1%
-1162.4%
Net Margin
-150.5%
6465.8%
Revenue YoY
22.6%
25.9%
Net Profit YoY
-62.2%
464.4%
EPS (diluted)
$-0.77
$1.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
PAVM
PAVM
Q3 25
$1.8M
Q2 25
$1.9M
Q1 25
$1.6M
Q4 24
$1.7M
Q3 24
$1.4M
$996.0K
Q2 24
$1.8M
$979.0K
Q1 24
$1.6M
$1.0M
Q4 23
$1.4M
$1.0M
Net Profit
IVF
IVF
PAVM
PAVM
Q3 25
$-2.6M
Q2 25
$-5.3M
Q1 25
$-17.4M
Q4 24
$-3.6M
Q3 24
$-1.6M
$64.4M
Q2 24
$-2.2M
$-10.8M
Q1 24
$-1.6M
$-15.2M
Q4 23
$-2.0M
$-14.0M
Gross Margin
IVF
IVF
PAVM
PAVM
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
31.0%
-38.7%
Q2 24
53.1%
-70.2%
Q1 24
45.3%
-72.7%
Q4 23
33.0%
-53.5%
Operating Margin
IVF
IVF
PAVM
PAVM
Q3 25
-93.1%
Q2 25
-160.4%
Q1 25
-1042.1%
Q4 24
-202.0%
Q3 24
-90.7%
-1162.4%
Q2 24
-100.9%
-1397.8%
Q1 24
-95.7%
-1389.7%
Q4 23
-109.2%
-1561.7%
Net Margin
IVF
IVF
PAVM
PAVM
Q3 25
-150.5%
Q2 25
-283.6%
Q1 25
-1060.1%
Q4 24
-211.3%
Q3 24
-113.8%
6465.8%
Q2 24
-122.2%
-1105.9%
Q1 24
-101.3%
-1506.1%
Q4 23
-144.4%
-1338.0%
EPS (diluted)
IVF
IVF
PAVM
PAVM
Q3 25
$-0.77
Q2 25
$-13.30
Q1 25
$-12.53
Q4 24
$14.86
Q3 24
$-15.11
$1.44
Q2 24
$-22.39
$-1.19
Q1 24
$-7.55
$-2.62
Q4 23
$-59.51
$-1.90

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
PAVM
PAVM
Cash + ST InvestmentsLiquidity on hand
$765.0K
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$-4.9M
Total Assets
$18.8M
$30.6M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
PAVM
PAVM
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$765.0K
Q2 24
$25.5M
Q1 24
$25.5M
Q4 23
$19.6M
Total Debt
IVF
IVF
PAVM
PAVM
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
IVF
IVF
PAVM
PAVM
Q3 25
$5.8M
Q2 25
$2.6M
Q1 25
$3.3M
Q4 24
$12.7M
Q3 24
$-23.3K
$-4.9M
Q2 24
$1.4M
$-73.9M
Q1 24
$10.2K
$-68.8M
Q4 23
$892.8K
$-53.8M
Total Assets
IVF
IVF
PAVM
PAVM
Q3 25
$18.8M
Q2 25
$19.3M
Q1 25
$31.7M
Q4 24
$46.4M
Q3 24
$17.0M
$30.6M
Q2 24
$17.8M
$39.4M
Q1 24
$17.3M
$37.3M
Q4 23
$18.5M
$33.1M
Debt / Equity
IVF
IVF
PAVM
PAVM
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
PAVM
PAVM
Operating Cash FlowLast quarter
$-1.8M
$-8.9M
Free Cash FlowOCF − Capex
$-1.8M
$-8.9M
FCF MarginFCF / Revenue
-101.6%
-892.5%
Capex IntensityCapex / Revenue
0.5%
0.6%
Cash ConversionOCF / Net Profit
-0.14×
TTM Free Cash FlowTrailing 4 quarters
$-7.8M
$-45.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
PAVM
PAVM
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.5M
Q4 24
$-617.4K
Q3 24
$-640.8K
$-8.9M
Q2 24
$-1.5M
$-11.7M
Q1 24
$-260.6K
$-13.1M
Q4 23
$-714.9K
$-11.9M
Free Cash Flow
IVF
IVF
PAVM
PAVM
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
$-8.9M
Q2 24
$-1.5M
$-11.7M
Q1 24
$-310.3K
$-13.2M
Q4 23
$-12.1M
FCF Margin
IVF
IVF
PAVM
PAVM
Q3 25
-101.6%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
-892.5%
Q2 24
-82.3%
-1190.9%
Q1 24
-19.7%
-1302.1%
Q4 23
-1149.4%
Capex Intensity
IVF
IVF
PAVM
PAVM
Q3 25
0.5%
Q2 25
0.5%
Q1 25
0.9%
Q4 24
4.6%
Q3 24
0.0%
0.6%
Q2 24
3.0%
0.3%
Q1 24
3.2%
4.2%
Q4 23
17.4%
Cash Conversion
IVF
IVF
PAVM
PAVM
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-0.14×
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons